Project Grant R21CA293319
- The University of Alabama at Birmingham (UAB) received a $192,780 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to implement and optimize a bundled screening program for breast and cervical cancer in a resource-limited setting in sub-Saharan Africa. The project aims to 1) establish the reach and effectiveness of the bundled screening program across stationary and mobile clinics, and 2) identify the implementation outcomes of...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $371,161 to develop advanced AI-based risk models for cervical cancer screening in low-resource settings. The project aims to leverage time-series imaging data and self-supervised learning to enhance the diagnostic accuracy of automated visual evaluation (AVE) models. The goal is to create a comprehensive risk stratification system that combines imaging data, HPV...
- This federal Project Grant award, totaling $477,869.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women, including African American women and Black African immigrant women. The key objectives are to: 1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among these populations,...
- The National Cancer Institute (NCI) awarded a $202,487 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to evaluate the adoption, implementation, and maintenance of thermal ablation, a cervical precancer treatment, in El Salvador. The project aims to investigate how features common to low- and middle-income countries shape the outcomes of integrating this evidence-based...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), provides $627,148.00 to the University of Maryland, College Park to develop an injectable, low-cost ablative therapy based on ethyl cellulose-ethanol gel for treating cervical dysplasia. The goal is to create an alternative to current costly and technically complex cervical cancer prevention solutions that are not practical for use in medically underserved regions. The project...
- The federal Project Grant award, titled "Implementation Strategies to Decentralize Breast Ultrasound Services and Facilitate Timely Breast Cancer Diagnoses in Rwanda", is funded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $691,176. The award aims to expand access to diagnostic breast ultrasound services in Rwanda by training non-radiologist clinicians and evaluating strategies for providing virtual supervision to maintain quality. Key...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico to conduct research focused on understanding the fundamental biological mechanisms of human papillomavirus (HPV)-induced tumors and precancerous lesions. The award aims to elucidate how inhibition of the MEK/ERK signaling pathway can lead to regression of HPV-driven tumors, with the goal of advancing scientific knowledge that can enable improved...
- This federal Project Grant award, totaling $696,140, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The grant aims to test a digital psychoeducation-activation tool and implementation strategy, called ICAN DEPCARE, to improve uptake of evidence-based depression treatment among cancer patients. The project, led by The Trustees of Columbia University in the City of New York, will conduct a clinic-level cluster randomized...
- This federal Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports efforts by a Columbia University researcher to develop and implement NCI-sponsored cancer clinical trials at the NCI-designated Herbert Irving Comprehensive Cancer Center (HICCC). The $193,926 award, with a project period from September 1, 2025 to August 31, 2030, will enable the researcher to: (1) develop novel HICCC investigator-led trials for...
- This federal Project Grant award of $317,420 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop and validate a patient-ready callascope device for cervical imaging and cancer prevention in low- and middle-income countries (LMICs). The primary focus is on creating point-of-care solutions for screening, diagnosis, and treatment that can be delivered by community health workers and midwives, thereby increasing access to care. Key...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $442,750.00 to New York University (NYU) to conduct a study on implementation strategies for cervical cancer control policies in Africa. The project aims to: (A) Engage a network of experts from African low- and middle-income countries (LMICs) and global agencies through a Delphi process to identify determinants of policy implementation success, using the Consolidated Framework for Implementation Research (CFIR) as a starting point. (B) Conduct qualitative interviews to understand the processes and mechanisms by which these determinants operate, leveraging the CFIR and Bullock et al.'s policy implementation framework. (C) Conduct another Delphi process to identify strategies from the ERIC compendium that could strengthen cervical cancer policy implementation in African LMICs. The award period is from September 23, 2025 through August 31, 2027. This research is expected to provide empirically-informed, expert-selected strategies to support effective implementation of cervical cancer control policies in LMICs, with broader applicability to other public health policy domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $442.8k | 9/22/25 |